SCHEMBL31228199

SCHEMBL31228199

[N-]=[N+]=N[C@]1(CO)O[C@@H](n2ccc3c(N)ncnc32)[C@@](F)(Cl)[C@@H]1O

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ADK P55263 1/20 0.40
PRMT5 O14744 17/20 0.38
WDR77 Q9BQA1 13/20 0.38
METTL3 Q86U44 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31228121 0.82 ADK (0.46) ADKPRMT5WDR77METTL3
SCHEMBL31228138 0.80 ADK (0.51) ADKPRMT5WDR77METTL3
SCHEMBL24198044 0.77 PDE4D (0.35)
SCHEMBL31228281 0.75 ADK (0.50) ADKPRMT5WDR77METTL3
SCHEMBL13471035 0.73 ADORA2A (0.48) ADKPRMT5WDR77METTL3
SCHEMBL18480770 0.73 ADK (0.52) ADKPRMT5WDR77METTL3
SCHEMBL18470916 0.73 ADK (0.52) ADKPRMT5WDR77METTL3
SCHEMBL31228504 0.72 ADK (0.47) ADKPRMT5WDR77METTL3
SCHEMBL24198052 0.72 POLA1 (0.35)
SCHEMBL31228240 0.71 PRMT5 (0.52) ADKPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705313-A2 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS The Scripps Research Institute (US) 2026-03-11 EP claimed
WO-2024227159-A2 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS THE SCRIPPS RESEARCH INSTITUTE (US) 2024-10-31 WO claimed
EP-4705313-A2 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS The Scripps Research Institute (US) 2026-03-11 EP disclosed
WO-2024227159-A2 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS THE SCRIPPS RESEARCH INSTITUTE (US) 2024-10-31 WO disclosed